Sanofi SA (NYSE:SNY) was the recipient of some unusual options trading on Tuesday. Traders acquired 651 put options on the company. This represents an increase of 666% compared to the average daily volume of 85 put options.

Sanofi (SNY) opened at $40.40 on Wednesday. The company has a debt-to-equity ratio of 0.25, a quick ratio of 1.26 and a current ratio of 1.70. Sanofi has a one year low of $38.14 and a one year high of $50.65. The company has a market capitalization of $102,499.30, a P/E ratio of 11.07, a PEG ratio of 2.16 and a beta of 0.92.

Sanofi (NYSE:SNY) last issued its earnings results on Wednesday, February 7th. The company reported $0.62 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $0.69 by ($0.07). Sanofi had a return on equity of 24.30% and a net margin of 23.25%. The business had revenue of $8.69 billion for the quarter, compared to the consensus estimate of $8.65 billion. During the same quarter in the prior year, the firm posted $1.25 earnings per share. The business’s revenue was down 2.1% compared to the same quarter last year. research analysts anticipate that Sanofi will post 3.36 earnings per share for the current fiscal year.

The firm also recently announced an annual dividend, which will be paid on Monday, June 4th. Stockholders of record on Thursday, May 10th will be paid a dividend of $1.8609 per share. This is an increase from Sanofi’s previous annual dividend of $1.58. This represents a dividend yield of 4.72%. The ex-dividend date of this dividend is Wednesday, May 9th. Sanofi’s payout ratio is currently 30.14%.

A number of research analysts have weighed in on SNY shares. Barclays upgraded Sanofi from an “underweight” rating to an “equal weight” rating in a research note on Wednesday, November 15th. Morgan Stanley downgraded Sanofi from an “overweight” rating to an “underweight” rating in a research note on Friday, December 1st. Bank of America downgraded Sanofi from a “buy” rating to a “neutral” rating in a research note on Wednesday, December 6th. JPMorgan Chase & Co. restated a “neutral” rating on shares of Sanofi in a research note on Thursday, December 14th. Finally, Cowen set a $48.00 price target on Sanofi and gave the company a “hold” rating in a research note on Monday, December 18th. Three investment analysts have rated the stock with a sell rating, ten have given a hold rating and two have given a buy rating to the stock. Sanofi has an average rating of “Hold” and a consensus price target of $49.33.

Hedge funds and other institutional investors have recently modified their holdings of the company. Bank of Nova Scotia Trust Co. bought a new position in shares of Sanofi during the 3rd quarter worth approximately $125,000. We Are One Seven LLC bought a new position in shares of Sanofi during the 4th quarter worth approximately $160,000. Bronfman E.L. Rothschild L.P. boosted its stake in shares of Sanofi by 46.0% during the 4th quarter. Bronfman E.L. Rothschild L.P. now owns 4,325 shares of the company’s stock worth $186,000 after acquiring an additional 1,362 shares during the period. SeaCrest Wealth Management LLC bought a new position in shares of Sanofi during the 4th quarter worth approximately $200,000. Finally, Mraz Amerine & Associates Inc. bought a new position in shares of Sanofi during the 3rd quarter worth approximately $204,000. Institutional investors own 8.94% of the company’s stock.

WARNING: “Sanofi Sees Unusually Large Options Volume (SNY)” was originally reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this article on another website, it was illegally stolen and reposted in violation of United States & international copyright & trademark law. The correct version of this article can be read at

Sanofi Company Profile

Sanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. Its segments are Pharmaceuticals, Human Vaccines (Vaccines), and Other. The Pharmaceuticals segment comprises the commercial operations of various franchises, including Speciality Care (Rare Diseases, Multiple Sclerosis, and Oncology), Diabetes and Cardiovascular, Established Prescription Products, Consumer Healthcare and Generics, and research and development, production and marketing activities for all of the Company’s pharmaceuticals operations.

Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with's FREE daily email newsletter.